Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

No Change in HF Outcomes When Private Equity Buys the Hospital

News Daily News

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

Michael O'Riordan

June 16, 2025

May 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

May 2025 Dispatch for the CV Team

May 20, 2025

April 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

April 18, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

May 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

May 01, 2024

Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF

News Conference News ESC 2023

Early SGLT2 Inhibition, Spot Urine Sodium Checks May Help in Acute HF

September 01, 2023

August 2023 News Roundup

News Opinion CV Team Dispatch

August 2023 News Roundup

August 01, 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

News Conference News ESC Heart Failure 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

May 25, 2023

Drugs to Tweak RAAS Response No Help in Acute COVID-19, RCTs Show

News Daily News

Drugs to Tweak RAAS Response No Help in Acute COVID-19, RCTs Show

April 19, 2023

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF

News Conference News ESC Heart Failure 2022

Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF

May 26, 2022

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

News Daily News

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

Yael L. Maxwell

May 21, 2020

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.